6-chloro-N-[3-(1H-imidazol-1-yl)-2-methylpropyl]-3-pyridinecarboxamide | 101457-26-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-chloro-N-[3-(1H-imidazol-1-yl)-2-methylpropyl]-3-pyridinecarboxamide
• 英文别名: 6-chloro-N-(3-imidazol-1-yl-2-methylpropyl)pyridine-3-carboxamide
• CAS: 101457-26-5
• 化学式: C₁₃H₁₅ClN₄O
• 分子量: 278.741
• InChiKey: ADRLLPMSAKELDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  59.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  6-氯烟酸 、 3-咪唑基-2-甲基丙胺 生成 6-chloro-N-[3-(1H-imidazol-1-yl)-2-methylpropyl]-3-pyridinecarboxamide
  参考文献：
  名称：

  Thromboxane synthetase enzyme inhibiting N-[(1H-imidazol-1-yl) and

  摘要：

  本发明涉及一种新型N-[(1H-咪唑-1-基)和(1H-1,2,4-三唑-1-基)烷基]吡啶-羧酰胺，其可用作抑制血栓素合酶和/或治疗高血压和心肌缺血的降压剂。

  公开号：

  US04555519A1

文献信息

• Thromboxane synthetase enzyme inhibiting N-[(1H-imidazol-1-yl) and
  申请人：American Cyanamid Company

  公开号：US04555519A1

  公开（公告）日：1985-11-26

  This invention concerns novel N-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)alkyl]pyridinecarboxamides which are useful as inhibitors of thromboxane synthetase and/or as hypotensive agents in the treatment of hypertension and myocardial ischemia.

  这项发明涉及新型N-[(1H-咪唑-1-基)和(1H-1,2,4-三唑-1-基)烷基]吡啶羧酰胺，它们可用作血栓素合成酶的抑制剂和/或作为治疗高血压和心肌缺血的降压剂。
• US4555519A
  申请人：——

  公开号：US4555519A

  公开（公告）日：1985-11-26
• Thromboxane synthetase inhibitors and antihypertensive agents. 3. N-[(1H-imidazol-1-yl)alkyl]heteroaryl amides as potent enzyme inhibitors
  作者：Jeffery B. Press、William B. Wright、Peter S. Chan、Margie F. Haug、Joseph W. Marsico、Andrew S. Tomcufcik

  DOI：10.1021/jm00389a013

  日期：1987.6

  The title compounds were prepared as the heterocyclic analogues of thromboxane (TX) synthetase inhibitors and antihypertensive agents previously reported from our laboratories. These compounds were at least as active TX synthetase inhibitors as their benzene isosteres with the indole derivatives 50-55 having the most potent enzyme inhibiting activity measured to date in our laboratories. The best compound, 54, is more than 200-fold more potent than the standard, dazoxiben. In contrast, the antihypertensive activity of these series of compounds was no better than their benzene counterparts and is far lower than the isoindoledione derivatives prepared in a related series. The structure-activity relationship results from this study were similar to our previous observations and include the fact that the amide moiety effectively replaces a carboxylic acid for potent TX synthetase inhibition and that a four to six methylene unit separation (approximately 8.5 A) between amide and imidazole moieties achieves maximal activity.